Advancements in CIDP treatment, including monoclonal antibodies and combination therapies, are setting new benchmarks in disease management and offering improved patient prognoses. https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947